Dexcom develops continuous glucose monitoring (CGM) devices. Diabetic patients use these to track their glucose levels in ...

BARCELONA, Spain--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for ...

In December, online rumors hinted at the fact that Dexcom may be planning to sunset its G6 CGM sensor model. The company has now started to notify patients of the discontinuation plan. The company ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly ...

DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...

Here's a look at the details in the report. The Details: DexCom reported quarterly earnings of 68 cents per share, which beat the Street estimate of 65 cents, according to data from Benzinga Pro.

Dexcom is continuing to evolve Stelo beyond basic glucose tracking, announcing a new wave of AI-powered features designed to help users better understand how food and daily habits affect their ...

People have been riding the GLP-1 wave to achieve quick and significant weight loss. But given the drug’s effect on controlling type 2 diabetes, it’s no surprise that DexCom CEO Jake Leach wants to ...

Dexcom Inc. failed to inform the market of manufacturing and accuracy problems with two models of continuous glucose monitors, leading to a series of stock selloffs when adverse news emerged, an ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...